Cellectis S.A. (NASDAQ:CLLS) Short Interest Update

Cellectis S.A. (NASDAQ:CLLS) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 340,300 shares, a drop of 25.4% from the March 31st total of 455,900 shares. Based on an average daily trading volume, of 338,600 shares, the short-interest ratio is presently 1.0 days. Currently, 0.7% of the company’s stock are sold short.

Hedge Funds Weigh In On Cellectis

A number of large investors have recently added to or reduced their stakes in CLLS. B Group Inc. acquired a new position in shares of Cellectis during the 4th quarter worth about $5,547,000. Millennium Management LLC purchased a new stake in Cellectis during the 4th quarter worth approximately $962,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 12,500 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Cellectis from a “hold” rating to a “buy” rating in a research note on Friday, April 25th.

Cellectis Trading Up 3.5 %

NASDAQ CLLS opened at $1.65 on Thursday. The company has a fifty day moving average of $1.33 and a 200 day moving average of $1.61. The company has a market capitalization of $91.44 million, a PE ratio of -1.27 and a beta of 3.22. Cellectis has a 1 year low of $1.10 and a 1 year high of $3.38. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $33.22 million for the quarter, compared to analysts’ expectations of $5.90 million. Research analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.